COMMUNIQUÉS West-GlobeNewswire

Inventiva announces the nomination of Andre Turenne as Director
28/03/2024
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur
28/03/2024
Daix (France), Long Island City (New York, États-Unis), le 28 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
28/03/2024
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197 ® , for vaccine development [...]
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
28/03/2024
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 28 March 2024, 08:00 a.m. CET alfapump ® – PMA 1 submitted to US FDA and accepted for substantive review, extensive feedback just received from FDA which is [...]
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
28/03/2024
Significant corporate and scientific progress in 2023 Innovations to End-to-End Platform technologies and IP portfolio Pipeline additions with multiple KRAS neoantigen targets Advancement of lead program MDG1015 with [...]
2023 Universal Registration Document
28/03/2024
Press Release Paris – March 28, 2024 – EUROAPI today announces that its 2023 Universal Registration Document will be filed with the French Financial Markets Authority (AMF) on April 5, 2024. Financial calendar May 22, [...]
Document d’Enregistrement Universel 2023
28/03/2024
Communiqué de presse Paris – Le 28 mars 2024 – EUROAPI annonce aujourd’hui que son Document d’Enregistrement Universel 2023 sera déposé auprès de l’Autorité des Marchés Financiers (AMF) le 5 avril 2024. Calendrier [...]
CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation
28/03/2024
High Precision System Uses Image Guidance to Target Tumor, Preserve Healthy Tissue & Reduce Risks of Complications such as ED LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, [...]
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
28/03/2024
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
28/03/2024
PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy [...]
Cannabix Technologies Announces Resignation of Kulwant Malhi
28/03/2024
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) reports that Kulwant Malhi has resigned as President and Director of [...]
Erasca Announces $45 Million Oversubscribed Private Placement Financing
28/03/2024
Funding from new and existing investors extends anticipated cash runway into H2 2026 SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company [...]
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
28/03/2024
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 [...]
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
27/03/2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Sharecare to report fourth quarter and full year fiscal 2023 financial results on Thursday, March 28
27/03/2024
ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report fourth quarter and full year [...]
Rakovina Therapeutics Announces Strategic Pivot to AI
27/03/2024
Company Leveraging Deep Docking AI Drug Discovery Platform VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical [...]
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27/03/2024
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions [...]
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
27/03/2024
SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to [...]
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
27/03/2024
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES- [...]

Pages